The new hub, which aims for revenues of over one billion euros and the listing of the stock on the Stock Exchange, will be led by the Golinelli family
by Aboutpharma Online editorial staff – February 17, 2015
A negotiation between Alfa Wassermann of Bologna and the activities of Sigma-Tau in the traditional pharmaceutical industry should come to light by the end of February, as reported in today's Corriere della Sera article by Fabio Tamburini. The new hub, which is expected to have revenues of over one billion euros, will be led by the Golinelli family, while most of Claudio Cavazza's heirs will leave the scene. “Alfa Wassermann and Sigma-Tau pharmaceutical industries, which represent about two thirds of the group, whose total turnover is around 700 million (with 2,000 employees), will merge into the new holding. While the Bolognese group, on the other hand, has revenues of over 400 million euros, in constant growth” explains Tamburini. "On the other hand, the activities in drugs for the treatment of rare diseases, which Sigma-Tau has developed above all in the United States, are not involved".
“The agreement with the Cavazza family was followed by Stephen Golinelli, the managing director of Alfa Wassermann, in turn the son of the founder, Marino Golinelli” concludes the journalist. “The pole that is being born will have Intesa Sanpaolo as a shareholder, currently a shareholder of Sigma-Tau with a 5 percent stake. The initial objective is the integration of the two groups and, after having reached one billion in revenues, the listing of the stock on the Stock Exchange”.
Related news: Golinelli, pole of made in Italy medicines (CORRIERE DELLA SERA)
Sigma-Tau and Alfa Wassermann in talks to merge activities in Italy (Fedaiisf 22/10/2014)
